Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Position Lessened by The Manufacturers Life Insurance Company

The Manufacturers Life Insurance Company reduced its holdings in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 1.7% during the 3rd quarter, HoldingsChannel reports. The firm owned 21,867 shares of the company’s stock after selling 379 shares during the quarter. The Manufacturers Life Insurance Company’s holdings in Amphastar Pharmaceuticals were worth $1,061,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently made changes to their positions in AMPH. GAMMA Investing LLC boosted its holdings in Amphastar Pharmaceuticals by 70.0% during the third quarter. GAMMA Investing LLC now owns 663 shares of the company’s stock valued at $32,000 after purchasing an additional 273 shares in the last quarter. Innealta Capital LLC bought a new position in shares of Amphastar Pharmaceuticals in the second quarter valued at approximately $55,000. Blue Trust Inc. raised its stake in shares of Amphastar Pharmaceuticals by 23.9% in the second quarter. Blue Trust Inc. now owns 1,604 shares of the company’s stock valued at $70,000 after acquiring an additional 309 shares during the last quarter. Asset Management One Co. Ltd. bought a new position in shares of Amphastar Pharmaceuticals in the third quarter valued at approximately $78,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its stake in shares of Amphastar Pharmaceuticals by 20.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,761 shares of the company’s stock valued at $85,000 after acquiring an additional 301 shares during the last quarter. 65.09% of the stock is owned by institutional investors and hedge funds.

Amphastar Pharmaceuticals Stock Performance

AMPH stock opened at $43.57 on Thursday. The company has a debt-to-equity ratio of 0.82, a current ratio of 3.43 and a quick ratio of 2.61. The company has a 50 day moving average price of $47.26 and a 200 day moving average price of $44.62. Amphastar Pharmaceuticals, Inc. has a fifty-two week low of $36.56 and a fifty-two week high of $65.92. The stock has a market capitalization of $2.09 billion, a PE ratio of 14.52, a price-to-earnings-growth ratio of 0.87 and a beta of 0.78.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on AMPH. Wells Fargo & Company began coverage on shares of Amphastar Pharmaceuticals in a research note on Friday, November 22nd. They issued an “equal weight” rating and a $55.00 target price for the company. StockNews.com cut shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, November 1st. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, Amphastar Pharmaceuticals currently has an average rating of “Hold” and an average target price of $60.33.

Insider Buying and Selling at Amphastar Pharmaceuticals

In related news, CFO William J. Peters sold 7,426 shares of the firm’s stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $52.05, for a total value of $386,523.30. Following the completion of the sale, the chief financial officer now directly owns 94,103 shares in the company, valued at approximately $4,898,061.15. This trade represents a 7.31 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Yakob Liawatidewi sold 5,214 shares of the firm’s stock in a transaction dated Wednesday, November 6th. The shares were sold at an average price of $52.05, for a total transaction of $271,388.70. Following the completion of the sale, the executive vice president now owns 74,938 shares of the company’s stock, valued at $3,900,522.90. This trade represents a 6.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 34,533 shares of company stock worth $1,676,542. Insiders own 27.10% of the company’s stock.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.